Life sciences

Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation

Monday, April 6, 2020 - 10:00pm

Regeneron also announced important changes to its accounting presentation effective January 1, 2020.

Key Points: 
  • Regeneron also announced important changes to its accounting presentation effective January 1, 2020.
  • The new Praluent agreements, effective April 1, 2020, simplify the antibody collaboration between the companies, increasing efficiency and streamlining operations.
  • In the U.S., Regeneron will have sole responsibility for Praluent and record net product sales.
  • Sanofi will have sole responsibility outside the U.S. and pay Regeneron a royalty on Praluent net product sales.

RTI International acquires Medical Data Analytics

Monday, April 6, 2020 - 7:14pm

RESEARCH TRIANGLE PARK, N.C., April 6, 2020 /PRNewswire/ -- RTI International has closed on its acquisition of Medical Data Analytics (MDA) , a provider of real-world evidence (RWE) generation to the pharmaceutical and biotechnology industry.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 6, 2020 /PRNewswire/ -- RTI International has closed on its acquisition of Medical Data Analytics (MDA) , a provider of real-world evidence (RWE) generation to the pharmaceutical and biotechnology industry.
  • "This acquisition fits directly with RTI's corporate strategy of investing in our pharmaceutical services and commercial research business lines," said E. Wayne Holden, PhD, president and CEO of RTI International.
  • "We are pleased to welcome the Medical Data Analytics team to RTI as we offer our clients deeper insights into the patient journey through the generation of clinical and economic evidence."
  • MDA employs a scientific, rigorous, and efficient method of data collection that uses screened and verified physicians as study investigators for data collection and validation.

Global Induced Pluripotent Stem Cell (iPSC) Industry

Monday, April 6, 2020 - 6:10pm

EXHIBIT 1: Worldwide Publication of hESC and hiPSC Research Papers for the Period 2008-2010, 2011-2013 and 2014-2016

Key Points: 
  • EXHIBIT 1: Worldwide Publication of hESC and hiPSC Research Papers for the Period 2008-2010, 2011-2013 and 2014-2016
    Induced Pluripotent: A Potential Competitor to hESCs?
  • EXHIBIT 3: Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
    EXHIBIT 5: Global Regenerative Medicines Market by Category: Breakdown (in %) for Biomaterials, Stem Cell Therapies and Tissue Engineering for 2019
    EXHIBIT 6: Leading Causes of Mortality Worldwide: Number of Deaths in Millions & % Share of Deaths by Cause for 2017
    EXHIBIT 7: Global Precision Medicine Market (In US$ Billion) for the Years 2018, 2021 & 2024
    EXHIBIT 8: Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
    EXHIBIT 9: Number of New Cancer Cases Reported (in Thousands) by Cancer Type: 2018
    EXHIBIT 10: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    EXHIBIT 11: Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for iPSCs Market
    EXHIBIT 13: New Gene-Editing Tools Spur Interest and Investments in Genetics, Driving Lucrative Growth Opportunities for iPSCs: Total VC Funding (In US$ Million) in Genetics for the Years 2014, 2015, 2016, 2017 and 2018
    Table 1: Induced Pluripotent Stem Cell (iPSC) Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025
    Table 2: Induced Pluripotent Stem Cell (iPSC) Market Share Shift across Key Geographies Worldwide: 2019 VS 2025
    Table 3: Vascular Cells (Cell Type) World Market by Region/Country in US$ Thousand: 2018 to 2025
    Table 4: Vascular Cells (Cell Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2019 VS 2025
    Table 5: Cardiac Cells (Cell Type) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025
    Table 6: Cardiac Cells (Cell Type) Market Sales Breakdown by Region/Country in Percentage: 2019 VS 2025
    Table 7: Neuronal Cells (Cell Type) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025
    Table 8: Neuronal Cells (Cell Type) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025
    Table 9: Liver Cells (Cell Type) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2018 to 2025
    Table 10: Liver Cells (Cell Type) Market Share Breakdown by Region/Country: 2019 VS 2025
    Table 11: Immune Cells (Cell Type) World Market by Region/Country in US$ Thousand: 2018 to 2025
    Table 12: Immune Cells (Cell Type) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025
    Table 13: Other Cell Types (Cell Type) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018 to 2025
    Table 14: Other Cell Types (Cell Type) Market Percentage Share Distribution by Region/Country: 2019 VS 2025
    Table 15: Cellular Reprogramming (Research Method) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2018 to 2025
    Table 16: Cellular Reprogramming (Research Method) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025
    Table 17: Cell Culture (Research Method) World Market by Region/Country in US$ Thousand: 2018 to 2025
    Table 18: Cell Culture (Research Method) Market Share Breakdown of Worldwide Sales by Region/Country: 2019 VS 2025
    Table 19: Cell Differentiation (Research Method) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025
    Table 20: Cell Differentiation (Research Method) Market Sales Breakdown by Region/Country in Percentage: 2019 VS 2025
    Table 21: Cell Analysis (Research Method) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025
    Table 22: Cell Analysis (Research Method) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025
    Table 23: Cellular Engineering (Research Method) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2
    Table 24: Cellular Engineering (Research Method) Market Share Breakdown by Region/Country: 2019 VS 2025
    Table 25: Other Research Methods (Research Method) World Market by Region/Country in US$ Thousand: 2018 to 2025
    Table 26: Other Research Methods (Research Method) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025
    Table 27: Drug Development & Toxicology Testing (Application) Global Opportunity Assessment in US$ Thousand by Region/Country: 2018-2025
    Table 28: Drug Development & Toxicology Testing (Application) Percentage Share Breakdown of Global Sales by Region/Country: 2019 VS 2025
    Table 29: Academic Research (Application) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025
    Table 30: Academic Research (Application) Market Share Shift across Key Geographies: 2019 VS 2025
    Table 31: Regenerative Medicine (Application) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2018-2025
    Table 32: Regenerative Medicine (Application) Market Share Breakdown by Region/Country: 2019 VS 2025
    Table 33: Other Applications (Application) Demand Potential Worldwide in US$ Thousand by Region/Country: 2018-2025
    Table 34: Other Applications (Application) Share Breakdown Review by Region/Country: 2019 VS 2025
    Table 35: United States Induced Pluripotent Stem Cell (iPSC) Market Estimates and Projections in US$ Thousand by Cell Type: 2018 to 2025
    Table 36: United States Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Cell Type: 2019 VS 2025
    Table 37: United States Induced Pluripotent Stem Cell (iPSC) Market Estimates and Projections in US$ Thousand by Research Method: 2018 to 2025
    Table 38: United States Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Research Method: 2019 VS 2025
    Table 39: United States Induced Pluripotent Stem Cell (iPSC) Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025
    Table 40: Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown in the United States by Application: 2019 VS 2025
    Table 41: Canadian Induced Pluripotent Stem Cell (iPSC) Market Estimates and Forecasts in US$ Thousand by Cell Type: 2018 to 2025
    Table 42: Induced Pluripotent Stem Cell (iPSC) Market in Canada: Percentage Share Breakdown of Sales by Cell Type for 2019 and 2025
    Table 43: Canadian Induced Pluripotent Stem Cell (iPSC) Market Estimates and Forecasts in US$ Thousand by Research Method: 2018 to 2025
    Table 44: Induced Pluripotent Stem Cell (iPSC) Market in Canada: Percentage Share Breakdown of Sales by Research Method for 2019 and 2025
    Table 45: Canadian Induced Pluripotent Stem Cell (iPSC) Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025
    Table 46: Canadian Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Application: 2019 VS 2025
    Table 48: Japanese Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Cell Type: 2019 VS 2025
    Table 50: Japanese Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Research Method: 2019 VS 2025
    Table 51: Japanese Demand Estimates and Forecasts for Induced Pluripotent Stem Cell (iPSC) in US$ Thousand by Application: 2018 to 2025
    Table 52: Induced Pluripotent Stem Cell (iPSC) Market Share Shift in Japan by Application: 2019 VS 2025
    Table 54: Chinese Induced Pluripotent Stem Cell (iPSC) Market by Cell Type: Percentage Breakdown of Sales for 2019 and 2025
    Table 56: Chinese Induced Pluripotent Stem Cell (iPSC) Market by Research Method: Percentage Breakdown of Sales for 2019 and 2025
    Table 57: Chinese Demand for Induced Pluripotent Stem Cell (iPSC) in US$ Thousand by Application: 2018 to 2025
    Table 58: Chinese Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Application: 2019 VS 2025
    Table 59: European Induced Pluripotent Stem Cell (iPSC) Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025
    Table 60: European Induced Pluripotent Stem Cell (iPSC) Market Share Shift by Region/Country: 2019 VS 2025
    Table 61: European Induced Pluripotent Stem Cell (iPSC) Market Estimates and Forecasts in US$ Thousand by Cell Type: 2018-2025
    Table 62: European Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Cell Type: 2019 VS 2025
    Table 63: European Induced Pluripotent Stem Cell (iPSC) Market Estimates and Forecasts in US$ Thousand by Research Method: 2018-2025
    Table 64: European Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Research Method: 2019 VS 2025
    Table 65: European Induced Pluripotent Stem Cell (iPSC) Addressable Market Opportunity in US$ Thousand by Application: 2018-2025
    Table 66: European Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Application: 2019 VS 2025
    Table 67: Induced Pluripotent Stem Cell (iPSC) Market in France by Cell Type: Estimates and Projections in US$ Thousand for the Period 2018-2025
    Table 68: French Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Cell Type: 2019 VS 2025
    Table 69: Induced Pluripotent Stem Cell (iPSC) Market in France by Research Method: Estimates and Projections in US$ Thousand for the Period 2018-2025
    Table 70: French Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Research Method: 2019 VS 2025
    Table 71: Induced Pluripotent Stem Cell (iPSC) Quantitative Demand Analysis in France in US$ Thousand by Application: 2018-2025
    Table 72: French Induced Pluripotent Stem Cell (iPSC) Market Share Analysis: A 7-Year Perspective by Application for 2
    Table 73: Induced Pluripotent Stem Cell (iPSC) Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Cell Type for the Period 2018-2025
    Table 74: German Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Cell Type: 2019 VS 2025
    Table 75: Induced Pluripotent Stem Cell (iPSC) Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Research Method for the Period 2018-2025
    Table 76: German Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Research Method: 2019 VS 2025
    Table 77: Induced Pluripotent Stem Cell (iPSC) Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025
    Table 78: Induced Pluripotent Stem Cell (iPSC) Market Share Distribution in Germany by Application: 2019 VS 2025
    Table 80: Italian Induced Pluripotent Stem Cell (iPSC) Market by Cell Type: Percentage Breakdown of Sales for 2019 and 2025
    Table 82: Italian Induced Pluripotent Stem Cell (iPSC) Market by Research Method: Percentage Breakdown of Sales for 2019 and 2025
    Table 83: Italian Demand for Induced Pluripotent Stem Cell (iPSC) in US$ Thousand by Application: 2018 to 2025
    Table 84: Italian Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Application: 2019 VS 2025
    Table 86: United Kingdom Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Cell Type: 2019 VS 2025
    Table 88: United Kingdom Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Research Method: 2019 VS 2025
    Table 89: United Kingdom Demand Estimates and Forecasts for Induced Pluripotent Stem Cell (iPSC) in US$ Thousand by Application: 2018 to 2025
    Table 90: Induced Pluripotent Stem Cell (iPSC) Market Share Shift in the United Kingdom by Application: 2019 VS 2025
    Table 91: Rest of Europe Induced Pluripotent Stem Cell (iPSC) Market Estimates and Forecasts in US$ Thousand by Cell Type: 2018-2025
    Table 92: Rest of Europe Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Cell Type: 2019 VS 2025
    Table 93: Rest of Europe Induced Pluripotent Stem Cell (iPSC) Market Estimates and Forecasts in US$ Thousand by Research Method: 2018-2025
    Table 94: Rest of Europe Induced Pluripotent Stem Cell (iPSC) Market Share Breakdown by Research Method: 2019 VS 2025
    Table 95: Rest of Europe Induced Pluripotent Stem Cell (iPSC) Addressable Market Opportunity in US$ Thousand by Application: 2018-2025
    Table 96: Rest of Europe Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Application: 2019 VS 2025
    Table 97: Induced Pluripotent Stem Cell (iPSC) Market in Asia-Pacific by Cell Type: Estimates and Projections in US$ Thousand for the Period 2018-2025
    Table 98: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Cell Type: 2019 VS 2025
    Table 99: Induced Pluripotent Stem Cell (iPSC) Market in Asia-Pacific by Research Method: Estimates and Projections in US$ Thousand for the Period 2018-2025
    Table 100: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Research Method: 2019 VS 2025
    Table 101: Induced Pluripotent Stem Cell (iPSC) Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by Application: 2018-2025
    Table 102: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market Share Analysis: A 7-Year Perspective by Application for 2019 and 2025
    Table 103: Rest of World Induced Pluripotent Stem Cell (iPSC) Market Estimates and Forecasts in US$ Thousand by Cell Type: 2018 to 2025
    Table 104: Induced Pluripotent Stem Cell (iPSC) Market in Rest of World: Percentage Share Breakdown of Sales by Cell Type for 2019 and 2025
    Table 105: Rest of World Induced Pluripotent Stem Cell (iPSC) Market Estimates and Forecasts in US$ Thousand by Research Method: 2018 to 2025
    Table 106: Induced Pluripotent Stem Cell (iPSC) Market in Rest of World: Percentage Share Breakdown of Sales by Research Method for 2019 and 2025
    Table 107: Rest of World Induced Pluripotent Stem Cell (iPSC) Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025
    Table 108: Rest of World Induced Pluripotent Stem Cell (iPSC) Market Share Analysis by Application: 2019 VS 2025

iBIO Commends Illinois the Life Sciences Community for its Impact through the iBIO COVID-19 PPE Response Fund

Monday, April 6, 2020 - 7:46pm

iBIO today announced that since the March 23rd launch of the iBIO COVID-19 PPE Response Fund , the Illinois life sciences community is making a significant impact in the fight against the coronavirus.

Key Points: 
  • iBIO today announced that since the March 23rd launch of the iBIO COVID-19 PPE Response Fund , the Illinois life sciences community is making a significant impact in the fight against the coronavirus.
  • Starting today and continuing each Monday, iBIO is posting weekly updates on the fund and its impact .
  • Astellas is the second Illinois-based life sciences company to offer significant support to the fund, following last weeks donation from Horizon Therapeutics .
  • The Illinois Biotechnology Innovation Organization (iBIO) is a life sciences industry association that represents the 85,000 life sciences employees at member companies, universities, service providers and venture firms.

Rafarma Establishes Advisory Board, Appoints First Member and Will Acquire Additional Patents and Intellectual Property

Monday, April 6, 2020 - 5:15pm

Rafarma will also enter into non-dilutive agreements with Dr. Laskavy to acquire all of his intellectual property and patents, including multiple United States, Australian and other International patents which include patents for cancer treatment and stem cell therapy.

Key Points: 
  • Rafarma will also enter into non-dilutive agreements with Dr. Laskavy to acquire all of his intellectual property and patents, including multiple United States, Australian and other International patents which include patents for cancer treatment and stem cell therapy.
  • The addition of Dr. Laskavy enables Rafarma to add multiple treatment options to the companys current Medicinal Marijuana treatment protocols.
  • Rafarma CEO Vladimir Dolgolenko stated: We feel the addition of Dr. Vladislav Laskavy to our advisory board will assist us in providing truly unique treatment options at our cutting-edge detox spas.
  • Rafarma is also excited to implement its own stem cell activation therapy using Dr. Laskavys patented techniques throughout the spas.

Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC

Monday, April 6, 2020 - 5:30pm

Onxeo will receive a one-time payment of $6.6 million from Acrotech in exchange for these rights.

Key Points: 
  • Onxeo will receive a one-time payment of $6.6 million from Acrotech in exchange for these rights.
  • In March 2019, Acrotech acquired from Spectrum Pharmaceuticals (SPPI) the license to belinostat for certain territories, including the United States, Canada, Mexico, and India.
  • The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories.
  • belinostat, an HDAC inhibitor (epigenetics), is licensed to Acrotech Biopharma LLC, a wholly-owned subsidiary of Aurobindo Pharma.

Prime Therapeutics launches PreserveRx(SM) gene therapy financial protection

Monday, April 6, 2020 - 2:00pm

EAGAN, Minn., April 6, 2020 /PRNewswire/ -- Prime Therapeutics LLC (Prime), together with BCS Insurance Company, today released its latest product, PreserveRxSM, the most robust gene therapy reinsurance solution in the market to date.

Key Points: 
  • EAGAN, Minn., April 6, 2020 /PRNewswire/ -- Prime Therapeutics LLC (Prime), together with BCS Insurance Company, today released its latest product, PreserveRxSM, the most robust gene therapy reinsurance solution in the market to date.
  • This clinical and financial solution is specifically designed to reinsure high-cost gene therapies for payers that cover these gene therapies and help preserve member access and coverage for these life-altering therapies.
  • First, its financial component seeks to provide payer relief associated with one of the covered gene therapies.
  • PreserveRx is offered by Prime and reinsured by BCS Insurance Company for Blue Plan payers looking for added protection from the extreme high cost gene therapies.

Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

Monday, April 6, 2020 - 3:23pm

WARREN, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2019.

Key Points: 
  • WARREN, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2019.
  • We are extremely pleased with the significant progress achieved with our clinical program for INOpulse to address multiple unmet cardiopulmonary diseases.
  • Research and development expenses for the fourth quarter ended December 31, 2019 were $2.8 million, essentially flat as compared to the prior year period.
  • General and administrative expenses for the fourth quarter ended December 31, 2019 were $1.4 million, compared to $1.9 million in the prior year period.

I-Mab Announces Upcoming Participation at April Conferences

Monday, April 6, 2020 - 2:04pm

Management presentation details are as follows:

Key Points: 
  • Management presentation details are as follows:
    Presentation: Tuesday,April 14, 2020 at9:20 10:00 a.m.
  • I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases.
  • Companys mission is to bring transformational medicines to patients through innovation.
  • The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities.

Surrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research

Monday, April 6, 2020 - 3:00pm

The Canada Gairdner Foundation annually designates five outstanding biomedical scientists who have made original contributions to medicine resulting in an increased understanding of human biology and disease.

Key Points: 
  • The Canada Gairdner Foundation annually designates five outstanding biomedical scientists who have made original contributions to medicine resulting in an increased understanding of human biology and disease.
  • Roel Nusse co-founded Surrozen, along with other leaders in Wnt biology, in 2016.
  • The Gairdner Award recognizes Dr. Nusses unique role at the epicenter of our understanding of Wnt biology.
  • Investors/Partners: Reza Afkhami VP, Corporate Development and Strategy Surrozen, Inc. reza@surrozen.com Media: Denise Powell Red House Consulting denise@redhousecomms.com